硼替佐米
地塞米松
多发性骨髓瘤
医学
肿瘤科
内科学
作者
Vânia Hungria,Paweł Robak,Marek Hus,Vera Zherebtsova,Christopher Ward,P. Joy Ho,Ana Carolina Ribas de Almeida,Roman Hájek,Kihyun Kım,Sebastian Grosicki,Hanlon Sia,Adam Bryant,Marcelo Pitombeira de Lacerda,Gracia Martínez,Anna Maria Sureda Balarí,Irwindeep Sandhu,Claudio Cerchione,Peter Ganly,Meletios Α. Dimopoulos,Chengcheng Fu
标识
DOI:10.1056/nejmoa2405090
摘要
Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI